Recent developments include the company’s delisting from Nasdaq in December 2025 and transition to OTC trading, as well as amendments to its securities purchase agreement limiting further financing closings.

• Meihua’s securities were delisted from Nasdaq in December 2025 and began trading on the OTC Marketplace under ticker MHUAF starting December 9, 2025.[S2]
• The company appealed the Nasdaq delisting decision but the appeal was denied in February 2026; a further review request was submitted in March 2026.[S2]
• On January 2, 2025, Meihua amended its securities purchase agreement to confirm no additional closings beyond the $6 million financing completed in January 2024.[S1]

The company’s established product portfolio and certifications position it well in the medical consumables market. Its extensive distribution network and cooperation with numerous hospitals provide broad market access. The introduction of SaaS solutions in 2025 adds a new revenue stream and potential for service-based growth. Strong liquidity ratios indicate financial stability to support operations and potential expansion. The company’s efforts to remediate internal control weaknesses may improve financial reporting reliability.

Revenue and net income declined significantly in 2025 compared to prior years, reflecting challenges in demand and profitability. The company’s internal control over financial reporting was assessed as not effective due to insufficient qualified accounting personnel, posing risks to financial accuracy and compliance. The delisting from Nasdaq and move to OTC trading may affect investor perception and liquidity. The company faces foreign exchange risks due to RMB/USD fluctuations and regulatory restrictions on dividend repatriation. Concentration risks exist with some customers and suppliers accounting for notable portions of revenues and purchases.

Meihua’s moat is supported by its long-standing presence in the Chinese medical consumables market, extensive product portfolio with regulatory certifications (FDA, CE), and a wide distribution network covering major global markets and thousands of domestic distributors and hospitals. The company’s ability to manufacture a broad range of Class I, II, and III medical devices and its recent expansion into SaaS solutions provide diversified revenue streams. Regulatory approvals and established customer relationships contribute to barriers to entry for competitors.

• Internal Control Weakness: The company identified material weaknesses in internal control over financial reporting due to insufficient accounting personnel with U.S. GAAP and SEC reporting expertise, which may affect financial statement reliability.
• Nasdaq Delisting: Meihua’s securities were delisted from Nasdaq in December 2025 and now trade on the OTC Marketplace, potentially impacting investor access and market liquidity.
• Revenue Decline: Revenues decreased by approximately 36% in 2025 compared to 2024, mainly due to decreased demand and economic conditions in China, affecting profitability.
• Foreign Exchange Risk: The company’s functional currency is RMB, but financial statements are reported in USD. Fluctuations in RMB/USD exchange rates may impact reported financial results.
• Customer and Supplier Concentration: While no single customer accounted for 10% or more of revenues in 2025, prior years showed some concentration. One supplier accounted for over 12% of purchases in 2025, posing concentration risk.

• Meihua International Medical Technologies Co., Ltd. is a China-based company engaged in manufacturing, research and development, and sales of Class I, II, and III medical devices with over 30 years of history.
• The company offers more than 800 domestic products and over 403 export products, including disposable infusion pumps, anesthesia puncture kits, electronic pumps, full anesthesia kits, urethral catheterization kits, gynecological examination kits, endotracheal intubation, dressing application, and various tubes.
• Meihua is a leading enterprise in China's medical consumables industry and holds manufacturing qualifications for Class I, II, and III medical device consumables in China, as well as FDA registration and EU CE certification.
• The company operates a global distribution network with 403 exporting distributors covering major international markets and 4409 distributors in China, along with direct sales channels cooperating with over 573 hospitals domestically.
• In fiscal year 2025, Meihua generated total revenues of approximately $61.79 million, down from $96.91 million in 2024, primarily due to decreased demand and economic factors in China.
• Net income for 2025 was approximately $6.78 million, a decrease from $10.84 million in 2024, mainly due to a decline in gross profit and increased operating expenses.
• The company started providing Software as a Service (SaaS) solutions in 2025, including cloud-based platform access, implementation services, and ongoing technical support, contributing about 2.62% of total revenue in 2025.
• Meihua's revenue is primarily derived from product sales (97.38% in 2025) with direct sales and distributor sales of disposable medical devices as main revenue streams.
• The company’s financial statements are prepared in U.S. dollars, while its functional currency is Renminbi (RMB). The RMB appreciated by 4.2% against the U.S. dollar in 2025.
• As of December 31, 2025, Meihua had cash and cash equivalents of approximately $16.93 million and current assets of about $153.58 million, with current liabilities of approximately $18.25 million, resulting in a strong current ratio of 8.42 and a cash ratio of 0.93.
• The company has short-term bank borrowings of about $8.99 million as of December 31, 2025, and no off-balance sheet arrangements were reported.
• Meihua entered into a securities purchase agreement in late 2023 with institutional investors for convertible notes and warrants, with a $6 million initial closing in January 2024 and no further closings planned after an amendment in January 2025.
• The company’s internal control over financial reporting was assessed as not effective as of December 31, 2025, due to insufficient accounting personnel with U.S. GAAP and SEC reporting knowledge; remedial measures are underway.
• Meihua’s shares were delisted from Nasdaq in December 2025 and subsequently began trading on the OTC Marketplace under the ticker MHUAF.
• The company’s audit committee consists of three independent members, including an audit committee financial expert.
• Meihua’s revenues are concentrated with no single customer accounting for 10% or more of total revenues in 2025, while one customer accounted for about 12.77% in 2024.
• The company’s product sales are mostly self-manufactured and resales of disposable medical devices from third-party manufacturers, with SaaS services newly introduced in 2025.
• The company’s financial instruments include cash, accounts receivable, bank acceptance receivables, due from related parties, accounts payable, other liabilities, accrued expenses, and short-term bank borrowings, with carrying amounts approximating fair value due to short maturities.